Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck

Autor: Sylvie Rottey, Desmond Curran, Andrzej Kawecki, Ricard Mesia, Jean-Pierre Delord, Jan B. Vermorken, Ricardo Hitt, D. de Raucourt, Fernando Rivera, Didier Cupissol, Heinz Roland Kienzer, A Gross, Marco Benasso, Carsten Bokemeyer, P. Koralewski
Jazyk: angličtina
Rok vydání: 2010
Předmět:
Oncology
Male
Colorectal cancer
cisplatin
Cetuximab
law.invention
Carboplatin
chemistry.chemical_compound
Randomized controlled trial
Quality of life
law
Antineoplastic Combined Chemotherapy Protocols
Medicine
Aged
80 and over
Antibodies
Monoclonal
Hematology
Middle Aged
Head and Neck Cancer
humanities
Survival Rate
Treatment Outcome
Head and Neck Neoplasms
Lymphatic Metastasis
Carcinoma
Squamous Cell
Female
Fluorouracil
medicine.drug
Adult
medicine.medical_specialty
Antibodies
Monoclonal
Humanized
recurrent and metastatic
Internal medicine
otorhinolaryngologic diseases
Humans
Survival rate
Aged
Neoplasm Staging
business.industry
Head and neck cancer
Original Articles
medicine.disease
Head and neck squamous-cell carcinoma
digestive system diseases
Surgery
stomatognathic diseases
chemistry
quality of life
Human medicine
Neoplasm Recurrence
Local
business
Zdroj: Annals of Oncology
Annals of oncology
ISSN: 1569-8041
0923-7534
Popis: Background: A phase III trial demonstrated that cetuximab is the first agent in 30 years to improve survival when added to platinum-based chemotherapy (platinum-fluorouracil) first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). This analysis of the trial assessed the impact of treatment on quality of life (QoL). Patients and methods: The European Organisation for Research and Treatment of Cancer QoL Questionnaire-Core 30 (QLQ-C30) and QLQ-Head and Neck 35 (QLQ-H&N35) module were used to assess QoL. Results: Of 442 patients randomly assigned, 291 (QLQ-C30) and 289 (QLQ-H&N35) patients completed at least one evaluable questionnaire. For QLQ-C30, cycle 3 and month 6 mean scores for platinum–fluorouracil plus cetuximab were not significantly worse than those for platinum–fluorouracil. Pattern-mixture analysis demonstrated a significant improvement in the global health status/QoL score in the cetuximab arm (P = 0.0415) but no treatment differences in the social functioning scale. For QLQ-H&N35, the mean score for the cetuximab arm was not significantly worse than that for the chemotherapy arm for all symptom scales at all post-baseline visits. At cycle 3, some symptom scores significantly favored the cetuximab arm (pain, swallowing, speech problems, and social eating). Conclusion: Adding cetuximab to platinum–fluorouracil does not adversely affect the QoL of patients with recurrent and/or metastatic SCCHN.
Databáze: OpenAIRE
Externí odkaz: